Accretion Nutraveda IPO

Listed SME Nutraceuticals
Min Investment
₹2,58,000
2000 Shares
Min Investment
₹2,58,000 · 2000 Shares
Price Band ₹122–129
Lot Size 1000 shares
Issue Size ₹25 Cr
Listed At ₹191.20 +48.2%
Subscribed 1.91×
Listed On BSE SME

Accretion Nutraveda IPO Listing Day Performance

Accretion Nutraveda listed on BSE SME on 04 February 2026 at ₹191.20, a 48.22% premium over the issue price of ₹129. A retail investor allotted the minimum application of 2,000 shares (2 lots) gained ₹1,24,400 at the listing price.

Issue price
₹129
final price
Listing price
₹191.20
pre-open auction
Listing gain
+48.22%
+₹62.2 per share
Profit per application
+₹1,24,400
2,000 shares

GMP vs actual listing

Last GMP before listing₹60 (+46.5%)
GMP-implied listing₹189
Actual listing₹191.20
Difference+₹2.2 (+1.2%)

Demand going into listing

Subscribed overall1.91×
QIB1.01×
NII2.42×
Retail2.19×
Listing price = opening price from the exchange's pre-open call auction on listing day. Watch live price

Market Sentiment

Grey Market Premium What is GMP?
+₹60
+46.5% ▲ ₹15 since last update
Est. listing ₹189
Issue price ₹129
GMP range ₹30 – ₹60
29 Jan · ₹30 03 Feb · ₹60
Updated 03 Feb, 12:00 am IST Unofficial grey-market data
GMP estimate ₹189
Actual listing ₹191.2
Listed above the GMP estimate by ₹2.2 (+1.2%)
Subscription Status
QIB
1.01x
NII
2.42x
bNII (>10L)
2.47x
sNII (2-10L)
2.33x
Retail
2.19x
Total
1.91x
Updated: Mar 02, 2026 11:41 pm IST
Analysis Score 56 / 100
Mixed Signals
Data: 80%
GMP Score · 44% weight 70
Subscription Score · 38% weight 25
Financial Health · 19% weight 83
Weighted average of the parts above; updates as GMP and subscription change. not investment advice.

IPO Details

Price Band₹122–129 per equity share
Face Value₹10 Per Equity Share
Lot Size 1000 shares (Min 2 lots · ₹2,58,000)
Total Issue Size ₹24.77 crore
Fresh IssueEntire issue — no offer for sale, so all proceeds go to the company
Issue TypeBook Build Issue
Lead Manager Sobhagya Capital Options Pvt. Ltd.
Registrar Kfin Technologies Ltd.
Listing atBSE SME
BSE Code544694
ISININE1KVQ01019
Listing Price₹191.20
Listing Gain+48.22%

Market Lot Size

Category Lots Shares Amount (₹)
Retail Minimum 2 2,000 ₹2,58,000
Retail Maximum 2 2,000 ₹2,58,000
S-HNI Minimum 3 3,000 ₹3,87,000
S-HNI Maximum 7 7,000 ₹9,03,000
B-HNI Minimum 8 8,000 ₹10,32,000

IPO Reservation

QIB 19.8% NII 15.1% Retail 35.1% Anchor 29.9%
Category Shares Offered Shares %
QIB3,62,00019.85%
NII (HNI)2,76,00015.13%
bNII > ₹10L1,84,00010.09%
sNII < ₹10L92,0005.04%
Retail6,40,00035.09%
Anchor5,46,00029.93%
Total18,24,000

Financial Analysis

Financial Data

ROE
81.22%
ROCE
36.98%
NAV/Share
₹14.72
Revenue Growth
208.85%
Profit Margin
16.25%

Financial Performance

2025 vs 2024 Revenue +208.8% Profit (PAT) +218.3% Total Assets +134.1%
Metric 2023 2024 2025 Sep 2025
Revenue 3.07 5.20 16.06 14.07
Expense 2.78 4.28 12.87 11.20
Profit (PAT) 0.28 0.82 2.61 2.33
Total Assets 4.06 4.64 10.86 16.35
Values in Crores (₹)

Peer Comparison

Company EPS P/E Market Cap (Cr)
Walpar Nutritions Ltd. 1.80 23.94 11
Influx Healthtech Limited 7.31 25.93 37
Peer median P/E 24.9x across 2 listed peers

Promoters & Holding Pattern

Promoters: Mr. Mayur Popatlal Sojitra, Mr. Ankurkumar Shantilal Patel, Mr. Paraskumar Vinubhai Parmar, Mr. Hardik Mukundbhai Prajapati, Mr. Harshad Nanubhai Rathod & Mr. Vivek Ashok Kumar Patel

Shareholding No. of Shares Holding %
Promoter Holding Pre Issue 53,20,000 100.00%
Promoter Holding Post Issue 72,40,000 73.48%

Strengths & Risks

Strengths
  • Revenue grew 209% in the latest reported year.
  • Solid profit margin — 16.3%.
  • Strong return on equity — 81%.
Risks & Concerns
  • Lists on the exchange's SME platform, where trading is usually thinner than on the main board — selling at your price can be harder.

From this issue's live data. Not investment advice — read the RHP.

Company Information

Accretion Nutraveda at a glance

From the company's description: “Accretion Nutraveda, since its incorporation in 2021, has been focused on the manufacturing of Ayurvedic and Nutraceutical products in India.”

Accretion Nutraveda is raising ₹24.77 crore through an IPO on the BSE SME in the Nutraceuticals sector. All of it is a fresh issue: there is no offer for sale, so every rupee raised goes to the company rather than to selling shareholders. Main stated uses of the fresh money: Purchase of Machineries for New Manufacturing Setup (₹8.03 crore), Funding working capital requirements of our company (₹5.5 crore) and Purchase of Machineries for Automation in existing Manufacturing unit (₹4.22 crore).

Revenue went from ₹3.07 crore in 2023 to ₹16.06 crore in 2025, up 423% over 2 years. Profit after tax went from ₹0.28 crore to ₹2.61 crore, a net margin of 16% in the latest year.

The promoters, led by Mr. Mayur Popatlal Sojitra, hold 100% before the issue and 73% after it — a dilution of 26.5 percentage points.

Written from the issue's offer-document figures shown on this page. Not investment advice.

Company Contact Information

Accretion Nutraveda Ltd., 27 Xcelon Industrial Park-1, Vasna-Chacharwadi, TaSanand,, Ahmedabad, Gujarat, 382213

Objects of the Issue

Purpose Amount (Cr)
Purchase of Machineries for Automation in existing Manufacturing unit 4.22
Purchase of Machineries for New Manufacturing Setup 8.03
Funding working capital requirements of our company 5.50
General Corporate Purpose -

Resources & Documents

Anchor Investors

Anchor Bidding Date
January 27, 2026
Shares Offered to Anchors
5,46,000
Lock-in End (30 Days, 50%)
March 04, 2026
Lock-in End (90 Days, 50%)
May 03, 2026

Accretion Nutraveda IPO - Quick Take

Accretion Nutraveda has set a price band of Rs 122–Rs 129 per share for an issue size of Rs 25 crore in the nutraceuticals sector. The stock listed with a 48.22% gain versus its issue price on February 04, 2026.

The company operates in the nutraceuticals space.

The issue is promoted by Mr. Mayur Popatlal Sojitra, Mr. Ankurkumar Shantilal Patel, Mr. Paraskumar Vinubhai Parmar, Mr. Hardik Mukundbhai Prajapati, Mr. Harshad Nanubhai Rathod & Mr. Vivek Ashok Kumar Patel with Sobhagya Capital Options Pvt. Ltd. acting as lead manager. Net proceeds will primarily be used towards purchase of Machineries for Automation in existing Manufacturing unit (Rs 4 crore) and purchase of Machineries for New Manufacturing Setup (Rs 8 crore).

On fundamentals, the company is posting revenue growth of 208.9%, a profit margin of 16.3%, return on equity of 81.2% in its most recent reported period. Listed peers in this segment include Influx Healthtech Limited (P/E 25.93x, market cap Rs 37 crore) and Walpar Nutritions Ltd. (P/E 23.94x, market cap Rs 11 crore) — useful reference points when evaluating the issue's pricing relative to where the broader sector is trading.

On our data-signal score, the combined signals for this issue currently read mixed — some indicators read positively and others do not. This is a summary of public data, not a recommendation to apply or skip. Past performance does not predict future returns — review the price chart and peer comparison below before trading.

Accretion Nutraveda IPO: Lead Manager & Registrar Track Record

How the firm running this issue and its registrar have fared on the other IPOs we track. Each firm's figures leave out Accretion Nutraveda itself, so they describe what came before it.

SME IPOs, last 12 months
  • Accretion Nutraveda listed at +48.2% on day one; the median of 193 listings was +1.5% (better than 88% of them).
  • Subscribed 1.91x against a median of 4.03x across 192 issues (higher than 30%).
  • Average listing-day move across all 194 SME listings we track: +11.6%.
Lead manager and registrar record on other IPOs we track
Firm Other IPOs Listed at / above issue Avg move Median
Sobhagya Capital Options Pvt. Ltd. Lead manager 3 0 MB · 3 SME 33% 1 of 3 −1.9% −0%
Kfin Technologies Ltd. Registrar 100 56 MB · 44 SME 81% 78 of 96 Check allotment →
Recent listings managed by Sobhagya Capital Options Pvt. Ltd. (3)

Best: Safety Controls +3.8% · Weakest: Paramount Syntex −9.5%

IPOListedListing-day move
Paramount Syntex 09 Oct 2026 −9.5%
Quanto Agroworld 22 Sep 2026 −0%
Safety Controls 13 Apr 2026 +3.8%
What a lead manager does

A SEBI-registered merchant banker that runs the issue: due diligence, drafting the offer document, setting the price band with the company, and marketing the IPO to investors.

What a registrar does

Finalises the basis of allotment, credits shares to demat accounts, releases blocked funds for unsuccessful bids and handles investor queries about the issue.

Listing-day move = exchange opening price vs issue price (band ceiling where the final price isn't recorded). Counts cover IPOs we track only. Past listings don't predict this one; this is not investment advice.

Frequently Asked Questions

Accretion Nutraveda listed at Rs 191.20 on 04 February 2026, against an issue price of Rs 129 — a 48.22% premium.

+48.22% at the listing price — Rs 62.2 per share, or Rs 1,24,400 on the minimum retail application of 2,000 shares.

The price band of Accretion Nutraveda IPO is Rs 122 to Rs 129 per share. Face value is Rs 10 per share.

The total issue size of Accretion Nutraveda IPO is Rs 25 crore, comprising fresh issue of Rs 25 crore.

The lot size of Accretion Nutraveda IPO is 1,000 shares. The minimum application is 2 lots (2,000 shares), requiring an investment of Rs 2,58,000.

Accretion Nutraveda IPO opens for subscription on January 28, 2026 and closes on January 30, 2026. Anchor investor bidding is scheduled for January 27, 2026.

The expected allotment date for Accretion Nutraveda IPO is February 02, 2026. Refunds for unsuccessful applicants are expected on February 03, 2026.

Accretion Nutraveda IPO is scheduled to list on February 04, 2026 on BSE. BSE script code: 544694, ISIN: INE1KVQ01019.

The last GMP (Grey Market Premium) recorded for Accretion Nutraveda IPO before listing was +Rs 60 (+46.5% over issue price). The shares actually listed at Rs 191.2 (+48.22% versus the issue price). GMP only estimates the listing price and stops mattering once the shares trade.

Accretion Nutraveda IPO was subscribed 1.91 times overall by the close of bidding — retail at 2.19x, QIB at 1.01x, NII at 2.42x.

Based on the final retail subscription of 2.19x for Accretion Nutraveda IPO, the estimated retail allotment probability is approximately 52.1%. This is a high probability of allotment.

The registrar for Accretion Nutraveda IPO is Kfin Technologies Ltd. After the allotment date, you can check your allotment status on the registrar's official website by entering your PAN, application number, or demat account details. Allotment status is also available on the BSE and NSE websites.

The book running lead manager(s) for Accretion Nutraveda IPO are Sobhagya Capital Options Pvt. Ltd.

The promoter(s) of Accretion Nutraveda are Mr. Mayur Popatlal Sojitra, Mr. Ankurkumar Shantilal Patel, Mr. Paraskumar Vinubhai Parmar, Mr. Hardik Mukundbhai Prajapati, Mr. Harshad Nanubhai Rathod & Mr. Vivek Ashok Kumar Patel.

Accretion Nutraveda IPO GMP — What It Means

Its last GMP before listing was 46.5%. Of the 34 SME IPOs we have tracked with a final GMP of 25% or more, 34 listed above, 0 flat and 0 below the issue price; Accretion Nutraveda listed 48.2% above its issue price.

See the full Accretion Nutraveda GMP history and trend, or learn how grey market premium works and how reliable it is.

Related IPO

Same sector or same stage as Accretion Nutraveda
Side by side: GMP, subscription, valuation, financials and listing performance.
0 Comments

No comments yet. Be the first to share your opinion!

GMPUpdate